Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Severe COVID-19
NCT04354714Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ruxolitinib in coronavirus disease 2019 (COVID-19), sponsored by Washington University School of Medicine. Planned start Jun 2020; status: withdrawn.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04354714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354714.